Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Meridia Withdrawn in US and Canada

October 11, 2010 7:55 am | by Matthew Perrone | News | Comments

Abbott Laboratories said it will withdraw its diet pill Meridia in the U.S. and Canada, after coming under pressure from health regulators who say the drug increases the risk of heart attack and stroke in patients with a history of heart disease.


Sanofi Laying Off 1,700 in US

October 11, 2010 7:53 am | by Linda A. Johnson | News | Comments

Sanofi-Aventis SA, the world's fourth-biggest drugmaker, said it is eliminating 1,700 jobs in its U.S. pharmaceutical business in a restructuring triggered by growing generic competition and other factors.


Mining for Trial Participants

October 11, 2010 7:42 am | by Ted Agres, Contributing Editor | Articles | Comments

Fifteen academic medical centers, research institutes, and major pharmaceutical companies are collaborating to enhance the speed and quality of clinical trials by harnessing patient data emerging from the coming widespread adoption of electronic health records.


Laying the IT Foundations

October 11, 2010 7:36 am | by David Chiang, Chief Executive Officer, Sage-N Research, Milpitas, Calif. | Articles | Comments

The development of effective data analysis and storage solutions for high-throughput mass spectrometry.


Expanding Nanotechnology

October 11, 2010 7:28 am | by Mike May, Contributing Editor | Articles | Comments

Nano-size approaches fan out across pharma.


High-Throughput Proof

October 11, 2010 7:21 am | by Victoria Echeverria BellBrook Labs, Madison, Wis.; Andrew Goulter, Wayne Bowen, Paul Wylie, TTP LabTech Ltd., Royston, U.K. | Articles | Comments

Validating a high-throughput angiogenesis assay using laser scanning cytometry.


Dual Purpose

October 11, 2010 6:58 am | by James Netterwald, PhD, MT (ASCP), Contributing Editor | Articles | Comments

New antibody-based therapies and emerging research tools bolster this multi-purpose molecule.


Precast Mini Gels

October 8, 2010 7:52 am | Product Releases | Comments

ProteaGel Precast Mini Gels are a great alternative to pouring your own SDS-PAGE gels due to the time savings and high resolution provided by a precast gel.


Biological Sequencing Software

October 8, 2010 7:46 am | Product Releases | Comments

Accelrys, Inc. announced the release of Accelrys Draw 4.0. Accelrys Draw enables scientists to draw, edit, compare, and explore complex biological sequences along with chemical structures and reactions, improving intellectual property management.


MorphoSys Buys Sloning for €19M

October 8, 2010 7:30 am | News | Comments

MorphoSys AG announced the acquisition of the private German company Sloning BioTechnology GmbH, a biotechnology company developing new methods of synthetic biology.


Cepheid And Novartis Working Together on Blood Test

October 8, 2010 7:27 am | News | Comments

Cepheid announced a collaboration with Novartis to commercialize a test for the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia.


VTX-1463 Effective Against Allergy Symptom

October 8, 2010 7:21 am | News | Comments

VentiRx Pharmaceuticals, Inc. announced results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.


Study Backs Safety of Caldolor

October 8, 2010 7:16 am | News | Comments

Cumberland Pharmaceuticals Inc. announced the publication of data affirming the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults.


J & J Asks for Dismissal in Kickback Case

October 8, 2010 7:11 am | by Denise Lavoie | News | Comments

Johnson & Johnson asked a federal judge to dismiss a complaint accusing the health care giant of paying millions in kickbacks so nursing homes would put more patients on its popular schizophrenia medication and other drugs.


Genzyme Board Rejects Sanofi Offer

October 8, 2010 7:06 am | by Linda A. Johnson | News | Comments

Biotech firm Genzyme Corp. said its board of directors has rejected Sanofi-Aventis SA's $69 per share offer and has recommended that Genzyme shareholders do not sell their shares to the French drugmaker.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.